Kyntra Bio, Inc. (NASDAQ:KYNB)
| Market Cap | 24.90M-46.0% |
| Revenue (ttm) | 4.62M+106.3% |
| Net Income | 183.19M+8967.0% |
| EPS | 58.19+3782.9% |
| Shares Out | 4.05M |
| PE Ratio | 0.11 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,500 |
| Open | 6.07 |
| Previous Close | 6.13 |
| Day's Range | 6.07 - 6.27 |
| 52-Week Range | 5.62 - 11.65 |
| Beta | 1.05 |
| Analysts | Hold |
| Price Target | 28.00(+355.28%) |
| Earnings Date | Nov 9, 2026 |
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About KYNB
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$KYNB stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in KYNB holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by KYNB's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
KYNB Estimated quarterly lobbying spending
Source: U.S. Senate LDA
KYNB Revenue by Segment or Geography
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New KYNB patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to KYNB from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in KYNB
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $888.31K |
| VXFVanguard Extended Market ETF | $328.82K |
Estimated from each fund’s disclosed top holdings × AUM
KYNB Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from KYNB’s recent data — informational, not investment advice